Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Hematology | Musculoskeletal | Family Medicine
 Disease Category: Multiple Myeloma
Location: United States, CA

Trial Information

Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination with Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients with High Risk Multiple Myeloma

You have been asked to participate in this research study because you have high risk or advanced Multiple Myeloma (MM) and will be undergoing an allogeneic hematopoietic stem cell transplant (HSCT, an infusion of bone marrow or stem cells from a family member or unrelated donor). The purpose of this study is to determine the highest possible dose of an anti-myeloma medication called bortezomib that can be given without causing unmanageable side effects as part of a preparation regimen before HSCT. The other part of the preparative regimen consists of two chemotherapy drugs, fludarabine (FLU) and melphalan (MEL), with or without total marrow irradiation (TMI) delivered by helical tomotherapy (HT). Your participation in this study is expected to last about 2 month for pre-treatment testing and treatment. After treatment on this study is over, your medical condition will be followed indefinitely.

Patient Inclusion/Exclusion Criteria:


- See http://clinicaltrials.coh.org for additional information.


City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Map

Research Center Information: City of Hope

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.